Adenocarcinoma of oesophagus: what exactly is the size of the problem and who is at risk?

PubWeight™: 1.74‹?› | Rank: Top 3%

🔗 View Article (PMC 1867797)

Published in Gut on March 01, 2005

Authors

J Lagergren1

Author Affiliations

1: Department of Surgical Sciences, Karolinska Institutet, Karolinska University Hospital,SE 17176 Stockholm, Sweden. jesper.lagergren@kus.se

Articles citing this

Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study. J Natl Cancer Inst (2011) 4.31

A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett's esophagus. Cancer Res (2009) 1.65

Adenocarcinoma of the esophagogastric junction: incidence, characteristics, and treatment strategies. Gastric Cancer (2010) 1.36

Epidemiology and risk factors for gastroesophageal junction tumors: understanding the rising incidence of this disease. Semin Radiat Oncol (2013) 1.28

Overexpression of Slug is associated with malignant progression of esophageal adenocarcinoma. World J Gastroenterol (2008) 1.20

Alcohol types and sociodemographic characteristics as risk factors for Barrett's esophagus. Gastroenterology (2008) 1.19

Incidence and survival of oesophageal and gastric cancer in England between 1998 and 2007, a population-based study. BMC Cancer (2012) 1.19

MicroRNA expression signatures during malignant progression from Barrett's esophagus to esophageal adenocarcinoma. Cancer Prev Res (Phila) (2013) 1.18

ErbB receptors in the biology and pathology of the aerodigestive tract. Exp Cell Res (2008) 1.17

Genome-wide catalogue of chromosomal aberrations in barrett's esophagus and esophageal adenocarcinoma: a high-density single nucleotide polymorphism array analysis. Cancer Prev Res (Phila) (2010) 1.12

Screening for Barrett's Esophagus. Gastroenterology (2015) 1.11

Barrett's esophagus and the increasing role of endoluminal therapy. Therap Adv Gastroenterol (2008) 1.11

Deferasirox (ICL670A) effectively inhibits oesophageal cancer growth in vitro and in vivo. Br J Pharmacol (2013) 1.09

Sex hormones and oesophageal adenocarcinoma: influence of childbearing? Br J Cancer (2005) 1.08

Effect of adiponectin and ghrelin on apoptosis of Barrett adenocarcinoma cell line. Dig Dis Sci (2007) 0.98

High intake of folate from food sources is associated with reduced risk of esophageal cancer in an Australian population. J Nutr (2010) 0.97

Esophageal malignancy: a growing concern. World J Gastroenterol (2012) 0.92

Effects of dietary fiber, fats, and meat intakes on the risk of Barrett's esophagus. Nutr Cancer (2009) 0.92

Oesophageal adenocarcinoma is associated with a deregulation in the MYC/MAX/MAD network. Br J Cancer (2008) 0.91

Current status and future perspectives on the etiology of esophageal adenocarcinoma. Front Oncol (2012) 0.89

Pre-treatment plasma proteomic markers associated with survival in oesophageal cancer. Br J Cancer (2012) 0.89

Systematic review: epidemiology of oesophageal cancer in Sub-Saharan Africa. Malawi Med J (2010) 0.87

Microbiome in reflux disorders and esophageal adenocarcinoma. Cancer J (2014) 0.86

Association between Helicobacter pylori seropositivity and digestive tract cancers. World J Gastroenterol (2009) 0.86

Detection of oesophageal cancer biomarkers by plasma proteomic profiling of human cell line xenografts in response to chemotherapy. Br J Cancer (2010) 0.84

Helicobacter pylori Seropositivity Is Associated with Gastric Cancer Regardless of Tumor Subtype in Korea. Gut Liver (2010) 0.83

Gastro-esophageal reflux disease symptoms and demographic factors as a pre-screening tool for Barrett's esophagus. PLoS One (2014) 0.83

Genome-wide methylation analysis shows similar patterns in Barrett's esophagus and esophageal adenocarcinoma. Carcinogenesis (2013) 0.83

Computer-assisted analysis of abrasive transepithelial brush biopsies increases the effectiveness of esophageal screening: a multicenter prospective clinical trial by the EndoCDx Collaborative Group. Dig Dis Sci (2010) 0.83

Presentation and prognosis of esophageal adenocarcinoma in patients below age 50. Dig Dis Sci (2008) 0.82

Molecular markers and imaging tools to identify malignant potential in Barrett's esophagus. World J Gastrointest Pathophysiol (2014) 0.81

Detection of erbB2 copy number variations in plasma of patients with esophageal carcinoma. BMC Cancer (2011) 0.80

Risk assessment of esophageal adenocarcinoma using γ-H2AX assay. Cancer Epidemiol Biomarkers Prev (2013) 0.80

Obesity and the rising incidence of oesophageal and gastric adenocarcinoma: what is the link? Gut (2007) 0.79

Epidemiology of Barrett's Esophagus and Esophageal Adenocarcinoma. Gastroenterol Clin North Am (2015) 0.79

Barrett's Esophagus: Emerging Knowledge and Management Strategies. Patholog Res Int (2012) 0.78

Role of body composition and metabolic profile in Barrett's oesophagus and progression to cancer. Eur J Gastroenterol Hepatol (2016) 0.78

Antireflux endoluminal therapies: past and present. Gastroenterol Res Pract (2013) 0.78

Demographic and lifestyle factors and survival among patients with esophageal and gastric cancer: The Biobank Japan Project. J Epidemiol (2017) 0.78

The Trend in Histological Changes and the Incidence of Esophagus Cancer in Iran (2003-2008). Int J Prev Med (2016) 0.78

Effects of refluxate pH values on duodenogastroesophageal reflux-induced esophageal adenocarcinoma. World J Gastroenterol (2011) 0.78

Molecular changes in the progression of Barrett's oesophagus. Postgrad Med J (2007) 0.78

Anxiety and depressive disorders among patients with esophageal cancer in Taiwan: a nationwide population-based study. Support Care Cancer (2014) 0.78

Mapping Local Cytosolic Enzymatic Activity in Human Esophageal Mucosa with Porous Silicon Nanoneedles. Adv Mater (2015) 0.76

Psychosocial factors and their association with reflux oesophagitis, Barrett's oesophagus and oesophageal adenocarcinoma. World J Gastroenterol (2013) 0.75

Biomarkers in the molecular pathogenesis of esophageal (Barrett) adenocarcinoma. Curr Oncol (2006) 0.75

Cost-Effectiveness Analysis on Endoscopic Surveillance Among Western Patients With Barrett's Esophagus for Esophageal Adenocarcinoma Screening. Medicine (Baltimore) (2015) 0.75

Undervalued criteria in the evaluation of multimodal trials for upper GI cancers. Cancer Invest (2014) 0.75

Exposure to gastric juice may not cause adenocarcinogenesis of the esophagus. World J Gastroenterol (2013) 0.75

Articles cited by this

Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med (1999) 17.30

Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA (1991) 11.53

Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer (1998) 10.17

Increasing prevalence of overweight among US adults. The National Health and Nutrition Examination Surveys, 1960 to 1991. JAMA (1994) 9.72

Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology (1997) 8.51

The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. Am J Gastroenterol (1997) 4.52

The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. N Engl J Med (1985) 4.30

Barrett's esophagus: development of dysplasia and adenocarcinoma. Gastroenterology (1989) 4.23

Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology (1993) 4.23

Aspirin use and risk of fatal cancer. Cancer Res (1993) 4.14

Tobacco, alcohol, and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst (1997) 4.09

Symptomatic gastroesophageal reflux: incidence and precipitating factors. Am J Dig Dis (1976) 3.71

Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst (1998) 3.66

Barrett's esophagus. N Engl J Med (1986) 3.62

Adenocarcinoma and Barrett's esophagus. An overrated risk? Gastroenterology (1984) 3.36

Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med (1999) 3.31

Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis. Ann Intern Med (2003) 3.30

An inverse relation between cagA+ strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma. Cancer Res (1998) 3.22

Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer (2001) 3.02

Obesity, alcohol, and tobacco as risk factors for cancers of the esophagus and gastric cardia: adenocarcinoma versus squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev (1995) 2.92

Adenocarcinoma of the esophagus: role of obesity and diet. J Natl Cancer Inst (1995) 2.83

The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia. JAMA (1995) 2.68

Helicobacter pylori infection and gastric atrophy: risk of adenocarcinoma and squamous-cell carcinoma of the esophagus and adenocarcinoma of the gastric cardia. J Natl Cancer Inst (2004) 2.63

The role of tobacco, snuff and alcohol use in the aetiology of cancer of the oesophagus and gastric cardia. Int J Cancer (2000) 2.58

Helicobacter pylori and gastroesophageal reflux disease: the bug may not be all bad. Am J Gastroenterol (1998) 2.51

Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res (1999) 2.51

Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev (1998) 2.43

Risk of adenocarcinomas of the esophagus and gastric cardia in patients with gastroesophageal reflux diseases and after antireflux surgery. Gastroenterology (2001) 2.34

A multiethnic population-based study of smoking, alcohol and body size and risk of adenocarcinomas of the stomach and esophagus (United States). Cancer Causes Control (2001) 2.31

Inverse association between intake of cereal fiber and risk of gastric cardia cancer. Gastroenterology (2001) 2.30

Assessing obesity: classification and epidemiology. Br Med Bull (1997) 2.29

Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J Natl Cancer Inst (1998) 2.26

Nutrient intake and risk of subtypes of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev (2001) 2.13

Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). J Natl Cancer Inst (1998) 2.09

Risk factors for esophageal cancer in Shanghai, China. I. Role of cigarette smoking and alcohol drinking. Int J Cancer (1994) 2.09

The rising trend in oesophageal adenocarcinoma and gastric cardia. Eur J Cancer Prev (1992) 2.05

Gastroesophageal reflux disease, use of H2 receptor antagonists, and risk of esophageal and gastric cancer. Cancer Causes Control (2000) 2.00

Opposing time trends of peptic ulcer and reflux disease. Gut (1998) 1.99

Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res (1998) 1.94

Value of endoscopic surveillance in the detection of neoplastic change in Barrett's oesophagus. Br J Surg (1988) 1.91

Etiology of Barrett's metaplasia and esophageal adenocarcinoma. Cancer Epidemiol Biomarkers Prev (1997) 1.88

Adenocarcinoma in Barrett's oesophagus: an overrated risk. Gut (1989) 1.88

Esophageal and gastric carcinoma in Norway 1958-1992: incidence time trend variability according to morphological subtypes and organ subsites. Int J Cancer (1997) 1.84

Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure. Gastroenterology (2000) 1.84

Association between medications that relax the lower esophageal sphincter and risk for esophageal adenocarcinoma. Ann Intern Med (2000) 1.83

A case-control study of cancer of the esophagus and gastric cardia in Linxian. Int J Cancer (1989) 1.75

Gastrointestinal cancer. Cancer (1995) 1.60

Tobacco, alcohol intake, and diet in relation to adenocarcinoma of the esophagus and gastric cardia. Cancer Causes Control (1993) 1.60

Heartburn and globus in apparently healthy people. Can Med Assoc J (1982) 1.58

Familial aggregation of Barrett's oesophagus, oesophageal adenocarcinoma, and oesophagogastric junctional adenocarcinoma in Caucasian adults. Gut (2002) 1.57

Increasing incidence of both major histological types of esophageal carcinomas among men in Sweden. Int J Cancer (1993) 1.57

Aspirin and reduced risk of esophageal carcinoma. Cancer (1995) 1.56

Role of Helicobacter pylori CagA+ strains and risk of adenocarcinoma of the stomach and esophagus. Int J Cancer (2003) 1.55

H. pylori and cagA: relationships with gastric cancer, duodenal ulcer, and reflux esophagitis and its complications. Helicobacter (1998) 1.52

Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells. Cancer Res (2000) 1.51

The increasing frequency of adenocarcinoma of the esophagus. Cancer (1989) 1.50

Adenocarcinoma of the esophagus and esophagogastric junction in white men in the United States: alcohol, tobacco, and socioeconomic factors. Cancer Causes Control (1994) 1.50

Familial aggregation of gastroesophageal reflux in patients with Barrett's esophagus and esophageal adenocarcinoma. Gastroenterology (1997) 1.46

Incidence of cancer of the esophagus in the US by histologic type. Cancer (1988) 1.40

Adenocarcinomas of the esophagus and gastric cardia: medical conditions, tobacco, alcohol, and socioeconomic factors. Cancer Epidemiol Biomarkers Prev (1996) 1.37

Determinants of survival following the diagnosis of esophageal adenocarcinoma (United States). Cancer Causes Control (1996) 1.35

Diet, obesity and reflux in the etiology of adenocarcinomas of the esophagus and gastric cardia in humans. J Nutr (2002) 1.32

Fruit and vegetable consumption in the prevention of oesophageal and cardia cancers. Eur J Cancer Prev (2001) 1.31

Family history of cancer and risk of esophageal and gastric cancers in the United States. Int J Cancer (2001) 1.29

Prospective evaluation of the prevalence of gastric Helicobacter pylori infection in patients with GERD, Barrett's esophagus, Barrett's dysplasia, and Barrett's adenocarcinoma. Am J Gastroenterol (2000) 1.28

Life-style, workplace, and stomach cancer by subsite in young men of Los Angeles County. Cancer Res (1990) 1.20

Familial Barrett's esophagus associated with adenocarcinoma. Gastroenterology (1992) 1.17

Familial gastroesophageal reflux and development of Barrett's esophagus. Ann Intern Med (1985) 1.16

Antioxidants and cancers of the esophagus and gastric cardia. Int J Cancer (2000) 1.11

Changing patterns and surgical results in adenocarcinoma of the oesophagus. Br J Surg (1997) 1.11

Trends in incidence rates of adenocarcinoma of the oesophagus and gastric cardia in New Zealand, 1978-1992. Int J Epidemiol (1996) 1.10

Improved survival in both histologic types of oesophageal cancer in Sweden. Int J Cancer (2002) 1.08

Adenocarcinoma arising in Barrett's esophagus. Dig Dis Sci (1989) 1.06

Body mass index and the risk of cancers of the gastric cardia and distal stomach in Shanghai, China. Cancer Epidemiol Biomarkers Prev (1997) 1.05

Familial Barrett esophagus and adenocarcinoma of the gastroesophageal junction. Cancer Epidemiol Biomarkers Prev (1993) 1.04

Helicobacter pylori infection is associated with a decreased risk of developing oesophageal neoplasms. Helicobacter (2001) 1.03

The consumption of tobacco, alcohol and the risk of adenocarcinoma in Barrett's oesophagus. Int J Cancer (1990) 1.01

Risk of esophageal and gastric adenocarcinomas in relation to use of calcium channel blockers, asthma drugs, and other medications that promote gastroesophageal reflux. Cancer Epidemiol Biomarkers Prev (1998) 1.00

Carcinoma arising in familial Barrett's esophagus. Am J Gastroenterol (1996) 0.99

Heredity and risk of cancer of the esophagus and gastric cardia. Cancer Epidemiol Biomarkers Prev (2000) 0.97

Utility of endoscopic screening for upper gastrointestinal adenocarcinoma. JAMA (2000) 0.94

Familial Barrett's oesophagus? Hepatogastroenterology (1986) 0.93

Helicobacter pylori infection: protection against Barrett's mucosa and neoplasia? Digestion (2000) 0.91

Adenocarcinoma in Barrett's esophagus. Semin Surg Oncol (1990) 0.89

[Trends in the occurrence of esophageal, cardial and stomach cancer in Denmark 1943-1982. Neoplasm statistics No. 19]. Ugeskr Laeger (1987) 0.86

Adenocarcinoma in the distal esophagus with and without Barrett esophagus. Differences in symptoms and survival rates. Arch Surg (1996) 0.85

Tobacco and alcohol intake in relation to adenocarcinoma of the gastric cardia in Spain. Cancer Causes Control (1994) 0.81